ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 2567 • ACR Convergence 2025

    Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study

    Tate Johnson1, Joshua Baker2, Punyasha Roul3, Grant Cannon4, Gary Kunkel5, Brian Sauer6, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3UNMC, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Salt Lake City VA/University of Utah, Salt Lake City, UT

    Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is over-represented in RA. A cardiometabolic multimorbidity (CMM) phenotype has emerged in the general population, but is…
  • Abstract Number: 2009 • ACR Convergence 2025

    Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout

    Patrick Williamson1, Rouhin Sen2 and Angelo Gaffo3, 1Tinsley Harrison Internal Medicine Residency, Department of Medicine, University of Alabama at Birmingham, Birmingham, 2University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology & Rheumatology, Birmingham, 3Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL

    Background/Purpose: Gout is associated with a 50% increased risk of cardiovascular disease (CVD).1 The current recommendation for evaluating CVD risk in gout is to use…
  • Abstract Number: 1658 • ACR Convergence 2025

    Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Omair Khan1, Halie Frideres2, Punyasha Roul3, Grant Cannon4, Gary Kunkel5, Brian Sauer6, Joshua Baker7, Ted Mikuls1, Bryant England1 and Tate Johnson1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC Department of Rheumatology, Omaha, NE, 3UNMC, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Existing cardiovascular disease (CVD) risk stratification strategies underperform in RA. Lung disease is an established CVD risk factor, and RA-interstitial lung disease (RA-ILD) clinically…
  • Abstract Number: 1314 • ACR Convergence 2025

    Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis

    Julia King1, Michael Duryee1, Punyasha Roul2, Katherine Wysham3, Grant Cannon4, Gary Kunkel5, John Richards6, Isaac Smith7, Beth Wallace8, Gail Kerr9, Andreas Reimold10, Pascale Schwab11, Daniel Anderson12, Wenxian Zhou13, Joshua Baker14, Ted Mikuls1, Bryant England1 and Tate Johnson1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 7Duke University Hospital, Durham, NC, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10Dallas VA Medical Center, Dallas, TX, 11VA Portland and Oregon Health & Science University, Portland, OR, 120587964, Durham, NC, 13University of Nebraska Medical Center, Bellevue, NE, 14University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
  • Abstract Number: 0614 • ACR Convergence 2025

    Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound

    Ileana C. Reynosa-Silva1, Oscar Azael Garza-Flores2, Fernanda M. Garcia-Garcia3, Aleydis Gonzalez-Melendez1, Iris J. Colunga-Pedraza3, Dionicio A. Galarza-Delgado3, Jose R Azpiri-Lopez4, Rosa Arvizu-Rivera5, Jesus Alberto Cardenas-de la Garza6 and Diego Azamat Salcedo Almanza7, 1Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 5Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, 6Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 7Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…
  • Abstract Number: 0437 • ACR Convergence 2025

    Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention

    Anokhi Saklecha1, Amelia Khoo2, Sierra Mendelsohn2, Abhijeet Danve3, Mei Xue Dong4 and Lisa Suter2, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, 4Yale-New Haven Medical Center, new haven, CT

    Background/Purpose: Rheumatoid arthritis (RA) is associated with a 1.5 to 2 fold increased risk of cardiovascular disease (CVD) due to systemic inflammation and endothelial dysfunction.…
  • Abstract Number: 2473 • ACR Convergence 2025

    Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm

    Carlos Valera Ribera1, Javier Narváez2, Joaquin Lacasa Molina3, Adrián Mayo-Juanatey4, Paula Mencio5, Patricia Leon Torralba5, Pablo Andujar Brazal5, Ignacio Vázquez Gómez6 and JUAN JOSE ALEGRE SANCHO7, 1Hospital Universitario Doctor Peset, València, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario Doctor Peset, Valencia, Spain, 4Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 5Hospital Universitario Doctor Peset, València, Comunidad Valenciana, Spain, 6H.U. Doctor Peset, Valencia, 7Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain

    Background/Purpose: Systemic sclerosis (SSc) is associated with both micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm estimates CV event risk in the…
  • Abstract Number: 1995 • ACR Convergence 2025

    The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study

    Chio Yokose1, Natalie McCormick2, Jiaqi Wang2, Sharan Rai3, leo lu4 and Hyon K. Choi5, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital/Harvard Medical School, Boston, MA, 4Arthritis Research Canada, Vancouver, BC, Canada, 5MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
  • Abstract Number: 1646 • ACR Convergence 2025

    The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes

    Queeneth Edwards1, Chukwuemelie Okeke2, Justin Riley3, Ufuoma Mamoh4 and Chekwube Obianyo5, 1Georgia Southern University, Statesboro, GA, 2Maimonides Medical Center, Brooklyn, NY, 3Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, 4Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, 5Georgia Southern University, statesboro

    Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
  • Abstract Number: 1186 • ACR Convergence 2025

    Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry

    Paul Cremer1, Michael Garshick2, Sushil Allen Luis3, Ajit Raisinghani4, Brittany Weber5, Vidhya Parameswaran6, Allison Curtis6, Sue Gibbons6, Allan Klein7 and John Paolini6, 1Cleveland Clinic, Shaker Heights, OH, 2NYU Langone Health, Tenafly, NJ, 3Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 4Division of Cardiology, Department of Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, 5Brigham and Women's Hospital, DEDHAM, MA, 6Kiniksa Pharmaceuticals, LEXINGTON, MA, 7Cleveland Clinic, Cleveland, OH

    Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease mediated by IL-1 that requires long-term treatment. While the 2015 European Society of Cardiology Guidelines position…
  • Abstract Number: 0604 • ACR Convergence 2025

    Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus

    Antonio Aznar-Esquivel1, Fuensanta Gómez-Bernal1, María García-González2, Marta Hernández Díaz1, Juan C. Quevedo-Abeledo3, Miguel A. González-Gay4 and Iván Ferraz Amaro1, 1Servicio Canario de Salud, La Laguna, Canarias, Spain, 2Servicio Canario de Salud, La Laguna, Spain, 3Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, 4Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

    Background/Purpose: The Metabolic Score for Insulin Resistance (METS-IR) is a recently developed index proposed as a predictor of cardiovascular (CV) events. In this study, we…
  • Abstract Number: 0435 • ACR Convergence 2025

    Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study

    Ahmad Alomari1, Reem Elmusa2, Nikita Shah3, Miguel Rodriguez4 and Diala Alawneh5, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/ HCA - North florida hospital, Gainesville, FL, 3UCF/HCA Florida North Florida Hospital, Gainesville, FL, 4SIMED Rheumatology, Gainesville, FL, 5University of Florida, Gainesville, FL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
  • Abstract Number: 2470 • ACR Convergence 2025

    Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis

    Attila Feher1, Morgan Emokpae2, Bindu Koyi2, Ibolya Csecs2, Baran Gunes3, Albert Sinusas2 and Monique Hinchcliff4, 1Yale University School of Medicine - New Haven, CT, New Haven, CT, 2Yale School of Medicine, New Haven, 3Yale University School of Medicine, Pompton Plains, NJ, 4Yale School of Medicine, Westport, CT

    Background/Purpose: Cardiovascular death ranks as the second leading cause of mortality related to systemic sclerosis (SSc), with coronary microvascular dysfunction (CMVD) likely contributing to this…
  • Abstract Number: 1993 • ACR Convergence 2025

    Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout

    Tingting Zhang1, Christian W. Mende2, Ashraf El-Meanawy3, Michael Pillinger4, Kaiding Zhu5, Bradley Marder6 and Brian Lamoreaux7, 1Amgen, Inc., Thousand Oaks, 2University of California San Diego, San Diego, CA, 3Medical College of Wisconsin, Milwaukee, WI, 4New York University Grossman School of Medicine, New York,, NY, 5Amgen, Inc., San Francisco, CA, 6AMGEN, Inc, Denver, CO, 7Amgen, Inc., Deerfield, IL

    Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
  • Abstract Number: 1623 • ACR Convergence 2025

    The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis

    Katarina Kmetova1, Gavin Poppei2, Kavya Sugur3, Julia Ford4, Wenying Liang4, Emily Chong4, Srilakshmi Yalavarthi4, NaveenKumar Somanathapura4, Nataliya Milman5, Peter Merkel6, Ora Singer7 and Yu (Ray) Zuo4, 1Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 2University of Michigan, Ann arbor, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5the Ottawa Hospital, Ottawa, ON, Canada, 6University of Pennsylvania, Philadelphia, PA, 7University of Michigan, Huntington Woods, MI

    Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology